73
Participants
Start Date
June 12, 2019
Primary Completion Date
May 31, 2038
Study Completion Date
May 31, 2038
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
The Children's Hospital at Westmead, Westmead
Murdoch Children's Research Institute, Parkville
Alfred I. duPont Hospital for Children, Wilmington
Emory University, Decatur
Cincinnati Childrens Hospital, Cincinnati
Medical College of Wisconsin, Children's Hospital, Milwaukee
Ann Robert and H. Lurie Children's Hospital of Chicago, Chicago
Baylor College of Medicine, Houston
Harbor - UCLA Medical Center, Torrance
Children's Hospital & Research Center Oakland, Oakland
Vanderbilt University Medical Center, Nashville
Osaka University, Osaka
Saitama Children's Medical Center, Saitama
Tokushima University Hospital, Tokushima
Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital, London
Sheffield Children's NHS Foundation Trust, Sheffield
Lead Sponsor
BioMarin Pharmaceutical
INDUSTRY